Natera, Inc. (NTRA) Stock Analysis 2026
BriMind AI Score
ProprietaryScore based on historical price CAGR, revenue growth, analyst upside, and valuation factors. Updated daily.
BriMind 1-Year Price Target
An even blend of the BriMind AI model's DCF and momentum target ($575.19) and Wall Street's consensus target ($403.89).
AI scores and price targets are for informational and educational purposes only. They do not constitute financial advice or a recommendation to buy or sell any security. Past performance is not indicative of future results. Always conduct your own research before making investment decisions. Full Disclaimer →
About Natera, Inc.
Natera applies cell-free DNA analysis across three areas: women's health, where Panorama screens for fetal chromosomal conditions; oncology, where Signatera detects molecular residual disease after cancer treatment; and organ health, where Prospera monitors transplant rejection. Signatera is the strategic centre of the growth story, because monitoring cancer patients for recurrence generates repeated testing over years rather than a single test.
How Natera Makes Money
Revenue comes from test volumes billed to insurers, Medicare, and patients, with average revenue per test heavily dependent on reimbursement coverage decisions. The distinguishing economic feature is longitudinal testing: a Signatera patient is tested repeatedly during surveillance, so each new patient represents a multi-year revenue stream rather than a one-time payment. Gross margin improves as reimbursement broadens and laboratory volumes scale against fixed costs.
Natera Revenue & Profitability Breakdown
This chart shows how Natera's revenue flows through to profit. Each row deducts a layer of costs: first the direct cost of making products/services (Cost of Revenue), then operating expenses like marketing and R&D, then taxes. What remains at the bottom is net income — the actual profit shareholders own. High gross and net margins indicate a business with strong pricing power and efficiency.
Key Financial Metrics
Natera, Inc. doesn't carry a meaningful trailing P/E right now, generates $104.0M in free cash flow, runs a debt/equity ratio of 13.09, and converts shareholder equity into profit at a -12.5% return on equity. For context: P/E ratio measures how much you pay for $1 of earnings (lower = cheaper, but fast-growing companies command higher P/E); Free Cash Flow is the cash left after running the business; Debt/Equity shows how leveraged a company is; Return on Equity shows how efficiently it turns shareholder capital into profit.
Wall Street Analyst Consensus
Wall Street analysts covering Natera, Inc. currently haven't converged on a clear consensus rating, with a mean 12-month price target of $336.74 (-14.4% vs the current price). Analysts set these targets after researching a company's earnings, competitive position, and industry trends — Strong Buy / Buy means the majority expect meaningful upside, while Hold means fair value near the current price rather than a sell signal.
Technical Price Signals
NTRA is currently in a golden cross pattern, trading above its 50-day average of $287.76 and above its 200-day average of $233.80. Moving averages smooth out day-to-day volatility to reveal the underlying trend — a Golden Cross (50MA crosses above 200MA) is a classic bullish signal, a Death Cross is bearish, though both are lagging indicators that confirm trends rather than predict them.
NTRA Investment Case: Bull vs Bear
NTRA's investment case breaks down into 4 bull points and 4 bear points below. The bull case outlines the key reasons the stock could outperform — competitive advantages, growth catalysts, and market tailwinds. The bear case highlights the most significant risks. A strong bull case with manageable bear risks typically makes for a more compelling investment.
Bull Case (Reasons to Buy)
- Signatera's recurring surveillance testing model produces compounding revenue per patient that single-test diagnostics cannot match.
- Expanding reimbursement coverage across more tumour types converts existing clinical demand into collected revenue.
- A large portfolio of published clinical evidence supports payer coverage decisions and physician adoption.
- Three distinct clinical franchises — women's health, oncology, organ health — reduce reliance on any single product.
Bear Case (Key Risks)
- Revenue per test depends on payer decisions, so coverage denials or rate reductions hit revenue without any volume change.
- Molecular residual disease testing is attracting well-funded competitors including large diagnostics companies.
- Heavy research and development plus commercial investment has historically constrained profitability.
- The stock trades on growth expectations, making it vulnerable to any deceleration in test volume or reimbursement progress.
What to Watch: NTRA Key Metrics
NTRA Stock — Frequently Asked Questions
Compare NTRA with Peers
More Healthcare Stock Analysis
In-depth reports on companies operating alongside NTRA — business models, bull and bear cases, and the metrics that matter.
Unlock the Full NTRA Analysis
Interactive price charts, real-time AI signals, advanced DCF models, portfolio tracking, earnings analysis, and side-by-side peer comparisons. Start your 14-day free trial — no credit card required.